ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -9 مورد

Dupilumab: Drug information

Dupilumab: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Dupilumab: Patient drug information" and "Dupilumab: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Dupixent
Brand Names: Canada
  • Dupixent
Pharmacologic Category
  • Interleukin-4 Receptor Antagonist;
  • Monoclonal Antibody;
  • Monoclonal Antibody, Anti-Asthmatic
Dosing: Adult
Asthma, moderate to severe eosinophilic phenotype or oral glucocorticoid dependent

Asthma, moderate to severe eosinophilic phenotype or oral glucocorticoid dependent: Note: May be used as add-on therapy in patients with eosinophilic asthma that is inadequately controlled on standard therapies (eg, high-dose inhaled corticosteroid and long-acting beta agonist) who have an eosinophilic phenotype (eg, peripheral blood eosinophils ≥150 cells/mcL) and/or other coexisting type 2 inflammatory conditions (eg, atopic dermatitis, rhinosinusitis with nasal polyposis) that require cotreatment (Ref). A minimum of 4 months of treatment is suggested to determine efficacy (Ref).

SUBQ: 400 mg once, followed by 200 mg every other week.

OR

SUBQ: 600 mg once, followed by 300 mg every other week. Note: Preferred dosing for patients with glucocorticoid-dependent asthma and type 2 inflammatory conditions (Ref).

Atopic dermatitis, moderate to severe

Atopic dermatitis, moderate to severe: Note: For use as add-on therapy in patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

SUBQ: 600 mg once, followed by 300 mg once every other week. In patients controlled after 1 year of initial therapy, may consider extending dosing intervals to every 3 to 4 weeks (Ref).

Chronic obstructive pulmonary disease, refractory

Chronic obstructive pulmonary disease, refractory (prevention of exacerbations): Note: May be preferred systemic add-on therapy in patients with refractory eosinophilic chronic obstructive pulmonary disease (peripheral blood eosinophils ≥300 cells/mcL) who experience frequent exacerbations despite maximal standard therapies (eg, an inhaled glucocorticoid, long-acting beta-agonist and long-acting muscarinic antagonist) (Ref). Discontinue therapy after 6 to 12 months if not effective (Ref).

SUBQ: 300 mg once every other week (Ref).

Eosinophilic esophagitis

Eosinophilic esophagitis: Note: Some experts reserve for patients with comorbid atopic conditions (eg, severe asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps) or those who are refractory to or decline other treatments (Ref).

SUBQ: 300 mg once weekly.

Prurigo nodularis

Prurigo nodularis: Note: Recommended first-line systemic treatment for widespread or refractory disease (Ref).

SUBQ: 600 mg once, followed by 300 mg once every other week.

Rhinosinusitis, chronic, with nasal polyps

Rhinosinusitis, chronic, with nasal polyps:

Note: May consider as add-on therapy in patients not controlled with other therapy (including intranasal corticosteroids and/or surgery) (Ref). A minimum of 6 months of treatment is suggested to determine efficacy (Ref).

SUBQ: 300 mg once every other week. In patients who have complete control of symptoms, some experts consider extending dosing intervals to every 4 weeks (Ref).

Urticaria, chronic spontaneous

Urticaria, chronic spontaneous: SUBQ: 600 mg once, followed by 300 mg once every other week.

Missed doses: If a weekly dose is missed, administer the dose as soon as possible, and start a new weekly schedule from the date of the last administered dose. If an every-other-week dose is missed, administer within 7 days from the missed dose and then resume the original schedule. If the missed dose is not administered within 7 days, wait until the next dose on the original schedule.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Dupilumab: Pediatric drug information")

Dosage guidance:

Safety: Dosing interval varies by age and indication (eg, every week, every other week, every 4 weeks); use caution. Patients should be current with all age-appropriate immunizations prior to initiation.

Asthma, maintenance therapy

Asthma (moderate to severe), maintenance therapy:

Children 6 to <12 years: Prefilled pen, prefilled syringe:

Note: In children 6 to <12 years, an initial loading dose is not necessary. If patient has atopic dermatitis comorbidity, the dosing for atopic dermatitis (including the initial loading dose) should be used to determine dupilumab therapy.

15 to <30 kg: SUBQ: 300 mg every 4 weeks or 100 mg every other week. Note: The 100 mg biweekly dose was previously described in manufacturer labeling; however, it has been removed from the market, no longer appears in labeling, and cannot be achieved with currently available dosage forms (Ref).

≥30 kg: SUBQ: 200 mg every other week.

Children ≥12 years and Adolescents: Prefilled pen, prefilled syringe: SUBQ: Initial: 400 mg once (administered as two 200 mg injections), followed by a maintenance dose of 200 mg every other week or 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.

Corticosteroid-dependent asthma or comorbid moderate to severe atopic dermatitis: Prefilled pen, prefilled syringe: SUBQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.

Atopic dermatitis, moderate to severe

Atopic dermatitis, moderate to severe: Note: May be used in combination with topical corticosteroids or topical calcineurin inhibitors; reserve calcineurin inhibitors for problem areas such as the face, neck, intertriginous, and genital areas.

Infants ≥6 months and Children <6 years: Note: Prefilled syringe may be used in ages ≥6 months; prefilled pen is only for use in ages ≥2 years. An initial loading dose is not necessary in pediatric patients <6 years.

5 to <15 kg: SUBQ: 200 mg every 4 weeks.

15 to <30 kg: SUBQ: 300 mg every 4 weeks.

Children ≥6 years and Adolescents ≤17 years: Prefilled pen, prefilled syringe:

15 to <30 kg: SUBQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every 4 weeks.

30 to <60 kg: SUBQ: Initial: 400 mg once (administered as two 200 mg injections), followed by a maintenance dose of 200 mg every other week.

≥60 kg: SUBQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.

Adolescents ≥18 years: Prefilled pen, prefilled syringe: SUBQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.

Eosinophilic esophagitis

Eosinophilic esophagitis: Note: Prefilled syringe may be used in all approved ages; the prefilled pen is only for use in ages ≥2 years.

Children and Adolescents:

15 to <30 kg: SUBQ: 200 mg every other week.

30 to <40 kg: SUBQ: 300 mg every other week.

≥40 kg: SUBQ: 300 mg every week.

Rhinosinusitis with nasal polyps

Rhinosinusitis (chronic) with nasal polyps: Children ≥12 years and Adolescents: SUBQ: 300 mg once every other week.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Adverse Reactions (Significant): Considerations
Dermatologic and hypersensitivity reactions

Various dermatologic and hypersensitivity reactions have been reported, including skin rash, urticaria, erythema multiforme, erythema nodosum, angioedema, and serum sickness-like reaction (Ref). Other reactions have also been reported, including alopecia (areata), facial erythema, immune thrombocytopenia purpura, psoriasis, and Sweet syndrome (Ref).

Mechanism: Immediate hypersensitivity reactions (urticaria/angioedema): Non-dose-related; likely immunologic (ie, IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure) or due to histamine-releasing activity (Ref). Serum sickness-like reaction: Associated with high titers of antibodies to dupilumab. Alopecia areata, psoriasis: Unknown; alteration of immune signaling may upregulate T-helper type 1 (Th1) and Th17 pathways (Ref). Facial erythema: Unknown; proposed theories include hypersensitivity reaction, paradoxical flaring of allergic contact dermatitis, and seborrheic dermatitis-like reaction to facial Malassezia species (Ref).

Onset: Rapid; immediate hypersensitivity reactions; generally occur within 1 hour of administration, but have been reported 1 month after dupilumab injection (Ref). Delayed; serum sickness-like reaction occurred 10 days after first injection (Ref). Facial or neck erythema occurred an average of 11 weeks after initiation (Ref). Varied; alopecia areata has occurred 48 hours after the first injection up to 28 months of treatment (Ref). Psoriasis has occurred 1 month to 18 months after initiation (Ref).

Ocular effects

Ocular surface disorders, including conjunctivitis, blepharitis, keratitis, eye pruritus, and dry eye syndrome have been reported (Ref). Although most cases are mild to moderate with resolution occurring in 80% of cases despite continued treatment with dupilumab (Ref), cases of severe cicatrizing blepharoconjunctivitis have also been reported (Ref).

Mechanism: Unknown; one possible mechanism includes reduction in ocular cytokines provides environment for Demodex mites to grow, resulting in IL-17-mediated inflammation, eosinophilia, and systemic IL-13 inhibition indirectly leading to reduction in conjunctival goblet cells and mucin production, contributing to tear film insufficiencies and subsequent corneal erosions (Ref). Other possible mechanisms include unmasking of preexistent subclinical atopic or allergic inflammatory processes, increased expression of proinflammatory molecules (ie, OX40L), and a local immunodeficiency resulting in local bacterial and viral infections (Ref).

Onset: Varied; 2 weeks to ~4 months after initiation (Ref).

Risk factors:

• Severe atopic dermatitis (Ref). No increase in incidence of conjunctivitis in dupilumab-treated asthma, chronic rhinosinusitis with nasal polyps, or eosinophilic esophagitis (Ref)

• Previous history of allergic conjunctivitis (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adolescents and adults unless otherwise specified.

>10%:

Hematologic & oncologic: Eosinophilia (≥500 cells/mcL: 42%; ≥1,000 cells/mcL: 2% to 14%; ≥5,000 cells/mcL: <3%)

Immunologic: Antibody development (1% to 16%; neutralizing: 1% to 5%)

Infection: Viral infection (adults: 14%)

Local: Injection-site reaction (1% to 38%)

Respiratory: Upper respiratory tract infection (18%)

1% to 10%:

Gastrointestinal: Diarrhea (adults: 3% to 4%), gastritis (adults: 2%), toothache (adults: 1% to 2%)

Genitourinary: Urinary tract infection (adults: 3%)

Infection: Helminthiasis (children: 2%; including ascariasis, enterobiasis), herpes virus infection (≤4%; including herpes simplex infection, herpes zoster infection [including ophthalmic herpes zoster], oral herpes simplex infection)

Nervous system: Dizziness (adults: 3%), headache (adults: 8%), insomnia (adults: 1%)

Neuromuscular & skeletal: Arthralgia (2% to 3%), back pain (adults: 5%), myalgia (adults: 3%)

Ophthalmic: Conjunctivitis (adults: 1% to 10%) (table 1), eye pruritus (adults: 1%) (table 2)

Dupilumab: Adverse Reaction: Conjunctivitis

Drug (Dupilumab)

Placebo

Population

Dose

Indication

Number of Patients (Dupilumab)

Number of Patients (Placebo)

10%

2%

Adults

300 mg given every other week

Atopic dermatitis

529

517

1%

1%

Adults

300 mg given every other week

Chronic obstructive pulmonary disease

938

934

2%

1%

Adults

300 mg given every other week

Chronic rhinosinusitis with nasal polyposis

440

282

4%

1%

Adults

300 mg given every other week

Prurigo nodularis

152

157

Dupilumab: Adverse Reaction: Eye Pruritus

Drug (Dupilumab)

Placebo

Population

Dose

Indication

Number of Patients (Dupilumab)

Number of Patients (Placebo)

1%

0.2%

Adults

300 mg given every other week

Atopic dermatitis

529

517

Respiratory: Nasopharyngitis (adults: 5% to 8%), oropharyngeal pain (2%), rhinitis (adults: 3%)

<1%:

Cardiovascular: Thromboembolic complications (adults: acute myocardial infarction, cerebrovascular accident)

Gastrointestinal: Cholecystitis (severe; adults)

Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, serum sickness, serum sickness-like reaction)

Ophthalmic: Dry eye syndrome (adults), keratitis (adults)

Postmarketing (any population):

Cardiovascular: Aortic aneurysm (age ≥75 years) (Ref), eosinophilic granulomatosis with polyangiitis (Ref), vasculitis (including hypersensitivity angiitis) (Ref)

Dermatologic: Acne vulgaris (Ref), acute generalized exanthematous pustulosis (Ref), alopecia (areata) (Ref), burning sensation of skin (Ref), desquamation (Ref), discoloration of sweat (infectious pseudochromhidrosis) (Ref), erythema multiforme (Ref), erythema nodosum (Ref), erythema of skin, facial erythema (Ref), facial rash, papule of skin, pruritus (Ref), psoriasis (including nail psoriasis, pustular psoriasis) (Ref), rosacea-like face eruption (Ref), skin pain, skin rash, Sweet syndrome (Ref), vitiligo (Ref)

Gastrointestinal: Pancreatitis (Ref)

Hematologic & oncologic: Hodgkin lymphoma (Ref), immune thrombocytopenia (Ref), T-cell lymphoma (including cutaneous) (Ref)

Hypersensitivity: Angioedema (Ref), facial edema

Immunologic: Sarcoidosis (sarcoid-like granulomatosis and [neuro]sarcoid-like reaction) (Ref)

Infection: Influenza (Ref)

Nervous system: Sleep disturbance (including nocturnal dyspnea) (Ref)

Neuromuscular & skeletal: Arthritis (including psoriatic arthritis, seronegative arthritis) (Ref), arthropathy (enthesitis and enthesopathy) (Ref), joint swelling (Ref)

Ophthalmic: Blepharitis (Ref), blepharoconjunctivitis (Ref), conjunctival scarring (Ref), corneal perforation (Ref), corneal ulcer (Ref), eye irritation (Ref), iridocyclitis (Ref), keratoconjunctivitis (Ref), keratoconus (Ref), punctate keratitis (Ref)

Respiratory: Eosinophilic pneumonitis (Ref), epistaxis (Ref), pulmonary alveolar hemorrhage (Ref)

Miscellaneous: Granuloma (annulare) (Ref)

Contraindications

Known hypersensitivity to dupilumab or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Arthralgia and psoriatic arthritis: Arthralgia, including gait disturbances or decreased mobility associated with joint symptoms, has been reported, sometimes requiring hospitalization. May occur within days to months following initiation of therapy and has resolved with or without therapy discontinuation; psoriatic arthritis requiring treatment has been reported; symptoms resolved with and without therapy discontinuation; report new-onset or worsening joint symptoms to health care provider.

• Eosinophilia and vasculitis: In rare cases, patients may present with clinical features of eosinophilic pneumonia or eosinophilic granulomatosis with polyangiitis. Monitor for eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury, and/or neuropathy, especially upon reduction of oral corticosteroids. A causal association between dupilumab and these underlying conditions has not been established.

Disease-related concerns:

• Helminth infections: It is unknown if administration of dupilumab will influence a patient's response against parasitic infections; patients with known helminth infections were not studied. Adverse reactions of helminth infections were reported in pediatric patients 6 to 11 years of age who participated in the pediatric asthma development program. Therefore, patients with preexisting helminth infections should undergo treatment of the infection prior to initiation of dupilumab therapy. Patients who become infected during treatment and do not respond to anti-helminth therapy should discontinue dupilumab until the infection resolves.

• Psoriasis: Patients treated for atopic dermatitis and asthma have reported new-onset psoriasis, some with a family history of psoriasis. May occur weeks to months following initiation of therapy and resolved with and without discontinuation of therapy; patients maintained on dupilumab may require treatment of psoriasis symptoms.

Concurrent drug therapy issues:

• Corticosteroid therapy: Do not discontinue corticosteroids abruptly following initiation of dupilumab therapy. Reductions in corticosteroid dose should be gradual, if appropriate. Clinicians should note that a reduction in corticosteroid dose may be associated with withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Dosage form specific issues:

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Immunogenicity: Dupilumab antibodies, including neutralizing antibodies, may develop; may be associated with lower serum dupilumab concentrations.

• Vaccines: Patients should be up to date with all immunizations before initiating therapy. The manufacturer’s labeling states to avoid the use of live vaccines in patients treated with dupilumab since clinical trials excluded the use of live vaccines. A systematic review and Delphi consensus suggest that vaccination, including live vaccination, can be safely administered during dupilumab therapy. Vaccine timing and response evaluation during dupilumab is limited to a small number of patients and clinical scenarios (eg, outbreak). The decision and timing of vaccination should be evaluated in a shared decision-making capacity (Lieberman 2024).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution Auto-injector, Subcutaneous [preservative free]:

Dupixent: 300 mg/2 mL (2 mL); 200 mg/1.14 mL (1.14 mL) [contains polysorbate 80]

Solution Prefilled Syringe, Subcutaneous [preservative free]:

Dupixent: 100 mg/0.67 mL (0.67 mL [DSC]) [latex free; contains polysorbate 80]

Dupixent: 300 mg/2 mL (2 mL); 200 mg/1.14 mL (1.14 mL) [contains polysorbate 80]

Generic Equivalent Available: US

No

Pricing: US

Solution Auto-injector (Dupixent Subcutaneous)

200MG/1.14ML (per mL): $2,101.77

300 mg/2 mL (per mL): $1,198.01

Solution Prefilled Syringe (Dupixent Subcutaneous)

200MG/1.14ML (per mL): $2,101.77

300 mg/2 mL (per mL): $1,198.01

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Auto-injector, Subcutaneous:

Dupixent: 300 mg/2 mL (2 mL); 200 mg/1.14 mL (1.14 mL) [contains polysorbate 80]

Solution Prefilled Syringe, Subcutaneous:

Dupixent: 300 mg/2 mL (2 mL); 200 mg/1.14 mL (1.14 mL) [contains polysorbate 80]

Administration: Adult

SUBQ: Administer as a subcutaneous injection into the thigh or lower abdomen (avoiding areas within 2 inches of navel); caregiver may administer in upper arm. Rotate injection sites, including initial doses (administer 600 mg initial dose as two 300 mg injections at different sites; administer 400 mg initial dose as two 200 mg injections at different sites). Do not administer into skin that is tender, damaged, bruised, or scarred. Patients may self-administer injection after proper training. Allow solution to reach room temperature for 45 minutes (300 mg prefilled syringe or prefilled pen) or 30 minutes (200 mg prefilled syringe or prefilled pen; 100 mg prefilled syringe) prior to use; after removal from the refrigerator, must be used within 14 days or discarded. Do not heat prefilled pen in microwave, hot water, or direct sunlight; do not remove needle cap while allowing product to reach room temperature. Do not shake. Do not use if solution is discolored or contains particulate matter. Do not administer if window on prefilled pen is yellow (indicates pen has been used). Prefilled syringes and pens do not contain a preservative; discard unused portion. Refer to manufacturer's labeling for additional information.

Administration: Pediatric

Parenteral: Note: Prefilled syringe may be used in ages ≥6 months; prefilled pen is only for use in ages ≥2 years. Patients ≥12 years of age may self-administer injection under adult supervision after proper training; doses in patients <12 years of age should be administered by a properly trained caregiver.

SUBQ: Allow prefilled syringe/pen to reach room temperature for 45 minutes (300 mg prefilled syringe/pen) or 30 minutes (200 mg prefilled syringe/pen or 100 mg prefilled syringe) prior to use; do not remove needle cap while allowing product to reach room temperature; do not heat prefilled pen in microwave, hot water, or direct sunlight. Do not shake. Do not use if solution is discolored or contains particulate matter. Do not administer if window on prefilled pen is yellow (indicates pen has been used). Administer as a subcutaneous injection into the thigh or lower abdomen (avoiding areas within 2 inches of navel); caregiver may administer in patient's upper arm. Rotate injection sites, including initial doses (administer 600 mg initial dose as two 300 mg injections at different injection sites; administer 400 mg initial dose as two 200 mg injections at different injection sites). Do not rub skin after injection. Do not administer into skin that is tender, damaged, bruised, or scarred. Prefilled syringes and pens do not contain a preservative; discard unused portion.

Missed dose:

For once-weekly dosing: If a dose is missed, administer dose as soon as possible and start new weekly schedule from the date of last administered dose.

For every-other-week dosing: If a dose is missed, administer within 7 days from the missed dose and then resume the original schedule. If the missed dose is not administered within 7 days, wait until the next dose on the original schedule.

For every-4-weeks dosing: If a dose is missed, administer within 7 days from the missed dose and then resume the original schedule. If the missed dose is not administered within 7 days, a new schedule should be started based on the date next dose given.

Use: Labeled Indications

Asthma, moderate to severe eosinophilic phenotype or oral glucocorticoid dependent: Add-on maintenance treatment of moderate to severe asthma in adults and pediatric patients ≥6 years of age with an eosinophilic phenotype or with corticosteroid dependent asthma.

Limitations of use: Not indicated for the relief of acute bronchospasm or status asthmaticus.

Atopic dermatitis, moderate to severe: Treatment of moderate to severe atopic dermatitis in adults and pediatric patients ≥6 months of age whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Chronic obstructive pulmonary disease, refractory (prevention of exacerbation): Add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease and an eosinophilic phenotype.

Limitations of use: Not indicated for the relief of acute bronchospasm.

Eosinophilic esophagitis: Treatment of adult and pediatric patients ≥1 year of age, weighing ≥15 kg, with eosinophilic esophagitis.

Prurigo nodularis: Treatment of adult patients with prurigo nodularis.

Rhinosinusitis, chronic, with nasal polyps: Add-on maintenance treatment in adults and pediatric patients ≥12 years of age with inadequately controlled chronic rhinosinusitis with nasal polyps.

Urticaria, chronic spontaneous: Treatment of chronic spontaneous urticaria in adults and pediatric patients ≥12 years of age who remain symptomatic despite H1 antihistamine treatment.

Limitations of use: Not indicated for other forms of urticaria.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Efgartigimod Alfa: May decrease therapeutic effects of Fc Receptor-Binding Agents. Risk C: Monitor

Nipocalimab: May decrease therapeutic effects of Fc Receptor-Binding Agents. Risk C: Monitor

Rozanolixizumab: May decrease therapeutic effects of Fc Receptor-Binding Agents. Risk C: Monitor

Vaccines (Live): Dupilumab may increase adverse/toxic effects of Vaccines (Live). Risk X: Avoid

Reproductive Considerations

Outcome data following use of dupilumab in patients planning a pregnancy are limited (Bosma 2021). Consider the long half-life of monoclonal antibodies when treating patients planning to become pregnant (Pfaller 2021).

Pregnancy Considerations

Dupilumab is a humanized monoclonal antibody (IgG4). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).

Outcome data following use of dupilumab in pregnant patients are limited primarily to case reports (Akuffo-Addo 2023; Avallone 2024; Escolà 2023; Hong 2024; Khamisy-Farah 2021; Metko 2024).

Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes). Maternal asthma symptoms should be monitored every 4 to 6 weeks during pregnancy (ERS/TSANZ [Middleton 2020]; GINA 2024).

Data related to the use of monoclonal antibodies for the treatment of severe asthma during pregnancy are limited (GINA 2024). Use of monoclonal antibodies may be considered when conventional therapies are insufficient (ERS/TSANZ [Middleton 2020]). In general, monoclonal antibodies should not be initiated during pregnancy. The option to continue treatment in patients who become pregnant during therapy should be considered as part of a shared decision-making process (Dorscheid 2022; Pfaller 2021).

Therapies other than dupilumab are recommended for the treatment of atopic dermatitis (Adam 2023; Deleuran 2024; Vestergaard 2019) and chronic rhinosinusitis with nasal polyps (Fokkens 2023) in pregnant patients.

Data collection to monitor pregnancy and infant outcomes following exposure to dupilumab is ongoing. Health care providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (1-877-311-8972 or https://mothertobaby.org). Patients may also enroll themselves.

Breastfeeding Considerations

Dupilumab is present in breast milk.

Data related to the presence of dupilumab in breast milk are available from a lactating patient who restarted treatment for atopic dermatitis 2.5 months postpartum. Dupilumab 300 mg was given subcutaneously, and breast milk and maternal plasma were sampled 3 days later. Breast milk concentrations of dupilumab were ~1.3% of the maternal plasma (maternal plasma: 85.7 mg/L; breast milk: 1.1 mg/L) (Dekkers 2023). Outcome data following use in breastfeeding patients are limited (Alvarenga 2023; Di Lernia 2024; Kage 2020; Kage 2021).

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Use of monoclonal antibodies for the treatment of asthma in lactating patients may be considered when conventional therapies are insufficient; use of an agent other than dupilumab may be preferred (ERS/TSANZ [Middleton 2020]).

Monitoring Parameters

Monitor for signs/symptoms of arthralgia and psoriatic arthritis (consider rheumatological evaluation in patients with signs of arthralgia), hypersensitivity reactions, and ocular adverse effects (consider eye exam in patients with unresolved conjunctivitis); signs of infection; signs/symptoms of vasculitis or hypereosinophilia (eg, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy); blood eosinophil levels (1 month and 3 months after initiation, then periodically, or as often as every 2 to 4 weeks if eosinophils are>1,500 cells/mcL) (Fokkens 2023); signs/symptoms of psoriasis.

Asthma and chronic obstructive pulmonary disease: Exacerbations, symptom control, and lung function.

Chronic rhinosinusitis with nasal polyps: Monitor treatment response (eg, SNOT-22 test, smell tests, congestion scores, CT scan, nasal polyp score) at 6 months, 12 months, then annually (Fokkens 2023).

Mechanism of Action

Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by binding to the IL-4Rα subunit. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of proinflammatory cytokines, chemokines, nitric oxide, and IgE. However, the mechanism of dupilumab action has not been definitively established; important inflammatory components of asthma, atopic dermatitis, chronic obstructive pulmonary disease, chronic sinusitis with nasal polyps, and eosinophilic esophagitis are IL-4 and IL-13.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Vd: ~4.8 ± 1.3 L.

Metabolism: Monoclonal antibodies are primarily degraded into small peptides and amino acids by catabolism.

Bioavailability: 61% to 64%.

Time to peak: ~1 week.

Excretion: Clearance: The median time to non-detectable concentrations is 10 to 11 weeks (for 300 mg every 2 weeks), 13 weeks (for 300 mg weekly), and 9 weeks (for 200 mg every 2 weeks). In a population pharmacokinetic study, age did not affect clearance in ages ≥6 years; however, clearance is increased with age in infants ≥6 months to children ≤5 years.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Weight: Dupilumab trough concentrations were lower in subjects with higher body weight.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Dupixent;
  • (AR) Argentina: Dupixent;
  • (AT) Austria: Dupixent;
  • (AU) Australia: Dupixent;
  • (BE) Belgium: Dupixent;
  • (BG) Bulgaria: Dupixent;
  • (BR) Brazil: Dupixent;
  • (CH) Switzerland: Dupixent;
  • (CL) Chile: Dupixent;
  • (CN) China: Dupixent;
  • (CO) Colombia: Dupixent;
  • (CZ) Czech Republic: Dupixent;
  • (DE) Germany: Dupixent;
  • (DO) Dominican Republic: Dupixent;
  • (EC) Ecuador: Dupixent;
  • (EE) Estonia: Dupixent;
  • (EG) Egypt: Dupixent;
  • (ES) Spain: Dupixent;
  • (FI) Finland: Dupixent;
  • (FR) France: Dupixent;
  • (GB) United Kingdom: Dupixent;
  • (GR) Greece: Dupixent;
  • (HK) Hong Kong: Dupixent;
  • (HR) Croatia: Dupixent;
  • (HU) Hungary: Dupixent;
  • (IE) Ireland: Dupixent;
  • (IT) Italy: Dupixent;
  • (JP) Japan: Dupixent;
  • (KR) Korea, Republic of: Dupixent;
  • (KW) Kuwait: Dupixent;
  • (LB) Lebanon: Dupixent;
  • (LT) Lithuania: Dupixent;
  • (LU) Luxembourg: Dupixent;
  • (LV) Latvia: Dupixent;
  • (MX) Mexico: Dupixent;
  • (MY) Malaysia: Dupixent;
  • (NL) Netherlands: Dupixent;
  • (NO) Norway: Dupixent;
  • (NZ) New Zealand: Dupixent;
  • (PL) Poland: Dupixent;
  • (PR) Puerto Rico: Dupixent;
  • (PT) Portugal: Dupixent;
  • (QA) Qatar: Dupixent;
  • (RO) Romania: Dupixent;
  • (RU) Russian Federation: Dupixent;
  • (SA) Saudi Arabia: Dupixent;
  • (SE) Sweden: Dupixent;
  • (SG) Singapore: Dupixent;
  • (SI) Slovenia: Dupixent;
  • (SK) Slovakia: Dupixent;
  • (TW) Taiwan: Dupixent;
  • (ZA) South Africa: Dupixent
  1. Adam DN, Gooderham MJ, Beecker JR, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol. 2023;37(6):1135-1148. doi:10.1111/jdv.18922 [PubMed 36695072]
  2. Agnihotri G, Shi K, Lio PA. A Clinician's guide to the recognition and management of dupilumab-associated conjunctivitis. Drugs R D. 2019;19(4):311-318. doi:10.1007/s40268-019-00288-x [PubMed 31728936]
  3. Ahatov R, Good AJ, Joo M, Tipton S, Goodwin B, Kelly B. A rare case of aggressive cytotoxic T-cell lymphoma in a patient on dupilumab. JAAD Case Rep. 2022;24:112-114. doi:10.1016/j.jdcr.2022.04.023 [PubMed 35662852]
  4. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459-473. doi:10.1111/bjd.17869 [PubMed 30851191]
  5. Akuffo-Addo E, Nicholas MN, Lansang P. Reported pregnancy outcomes in women with severe atopic dermatitis treated with dupilumab: a systematic review. J Cutan Med Surg. 2023;27(2):177-178. doi:10.1177/12034754231152223 [PubMed 36721993]
  6. Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
  7. Alroobaea R, Rubaiee S, Hanbazazah AS, et al. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis. Eur Rev Med Pharmacol Sci. 2022;26(11):4074-4081. doi:10.26355/eurrev_202206_28977 [PubMed 35731078]
  8. Alvarenga JM, Maria Lé A, Torres T. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: a case report. Actas Dermosifiliogr. Published online October 17, 2023. doi:10.1016/j.ad.2023.10.005 [PubMed 37858861]
  9. Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110 [PubMed 33956488]
  10. Avallone G, Cavallo F, Tancredi A, et al. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: a nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 2024;38(9):1799-1808. doi:10.1111/jdv.19794 [PubMed 38284131]
  11. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. doi:10.1016/S0140-6736(19)31881-1 [PubMed 31543428]
  12. Bansal A, Simpson EL, Paller AS, et al. Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma. Am J Clin Dermatol. 2021;22(1):101-115. doi:10.1007/s40257-020-00577-1 [PubMed 33481203]
  13. Barbarin C, Hosteing S, Nosbaum A, Allouchery M, Celerier P. Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis. Eur J Dermatol. 2019;29(5):542-543. doi:10.1684/ejd.2019.3626 [PubMed 31789276]
  14. Barroso-García B, Rial MJ, Molina A, Sastre J. Alopecia areata in severe atopic dermatitis treated with dupilumab. J Investig Allergol Clin Immunol. 2018;28(6):420-421. doi:10.18176/jiaci.0301 [PubMed 30530389]
  15. Beaziz J, Bouaziz JD, Jachiet M, Fite C, Lons-Danic D. Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. Ann Dermatol Venereol. 2021;148(3):198-201. doi:10.1016/j.annder.2021.02.003 [PubMed 34175141]
  16. Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205-214. doi:10.1056/NEJMoa2303951 [PubMed 37272521]
  17. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9 [PubMed 30558872]
  18. Bohner A, Topham C, Strunck J, et al. Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. Cornea. 2021;40(5):584-589. doi:10.1097/ICO.0000000000002461 [PubMed 32826648]
  19. Bonis PA. Treatment of eosinophilic esophagitis (EoE). Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed April 23, 2025.
  20. Bosma AL, Gerbens LAA, Middelkamp-Hup MA, Spuls PI. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. Clin Exp Dermatol. 2021;46(6):1089-1092. doi:10.1111/ced.14725 [PubMed 33969522]
  21. Bridgewood C, Wittmann M, Macleod T, et al. T Helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T Helper 17‒type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol. 2022;142(10):2660-2667. doi:10.1016/j.jid.2022.03.013 [PubMed 35395222]
  22. Buchheit KM. Chronic rhinosinusitis with nasal polyposis: management and prognosis. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed April 23, 2025.
  23. Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm. [PubMed 6423951]
  24. Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. Front Immunol. 2020;11:1920. doi:10.3389/fimmu.2020.01920 [PubMed 33013843]
  25. Cheng J, Jiang L, Morrow NC, et al. Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis. J Am Acad Dermatol. 2021;85(1):265-267. doi:10.1016/j.jaad.2020.09.046 [PubMed 32956738]
  26. Dang N, Zheng H, Ren Y. A pediatric case of dupilumab-induced pustular psoriasis. J Dermatolog Treat. 2024;35(1):2333016. doi:10.1080/09546634.2024.2333016 [PubMed 38839072]
  27. DeGrazia TM, Raji K, Alshamekh S, Chisolm S. Psoriatic plaques after initiation of dupilumab therapy. Dermatitis. 2020;31(4):e36-e37. doi:10.1097/DER.0000000000000570 [PubMed 32665517]
  28. Dekkers C, El Amrani M, van Luin M, et al. Limited excretion of dupilumab into breastmilk: a case report. J Eur Acad Dermatol Venereol. 2023;37(9):e1154-e1155. doi:10.1111/jdv.19164 [PubMed 37143362]
  29. Deleuran M, Dézfoulian B, Elberling J, et al. Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: interdisciplinary expert consensus in Northern Europe. J Eur Acad Dermatol Venereol. 2024;38(1):31-41. doi:10.1111/jdv.19512 [PubMed 37818828]
  30. Di Lernia V, Peccerillo F. Long-term follow-up of dupilumab treatment during conception, pregnancy and lactation. Indian J Dermatol. 2024;69(2):193-195. doi:10.4103/ijd.ijd_447_23 [PubMed 38841220]
  31. Di Staso F, Lambiase A, Silvio Di Staso, Gattazzo I, Ciancaglini M, Scuderi G. Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis. Am J Ophthalmol Case Rep. 2022;25:101309. doi:10.1016/j.ajoc.2022.101309 [PubMed 35128157]
  32. Dorscheid DR, Lee JK, Ramesh W, Greenwald M, Del Carpio J. Guidance for administering biologics for severe asthma and allergic conditions. Can Respir J. 2022;2022:9355606. doi:10.1155/2022/9355606 [PubMed 36124286]
  33. Dupixent (dupilumab) [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Inc; April 2025.
  34. Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747-760. doi:10.1016/j.jaad.2020.07.025 [PubMed 32682025]
  35. Escolà H, Figueras-Nart I, Bonfill-Orti M, et al. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: clinical experience in 13 patients. J Eur Acad Dermatol Venereol. 2023;37(9):e1156-e1160. doi:10.1111/jdv.19165 [PubMed 37143399]
  36. Fernandez E, Chandler W, Long PR, Palmer ML, Fadugba O. Dupilumab-associated sweet Syndrome. Cutis. 2023;111(6):E7-E9. doi:10.12788/cutis.0798 [PubMed 37487126]
  37. Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023;61(3):194-202. doi:10.4193/Rhin22.489 [PubMed 36999780]
  38. Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opin Drug Saf. 2021;20(9):997-1004. doi:10.1080/14740338.2021.1939673 [PubMed 34114910]
  39. Frey S, Kendziora B, Holch JW, Lindner L, French LE, Wollenberg A. Immune thrombocytopenic purpura in a patient with atopic dermatitis treated with dupilumab. Acta Derm Venereol. 2021;101(3):adv00409. doi:10.2340/00015555-3734 [PubMed 33349889]
  40. Fritz AL, Lacy FA, Morrell DS. Angioedema: a potential complication of dupilumab in atopic dermatitis. Pediatr Dermatol. 2021;38(1):237-238. doi:10.1111/pde.14434 [PubMed 33099796]
  41. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. Updated May 2024. Accessed July 6, 2024.
  42. Grote C, Zirkenbach F, Wagner JN, Augustin M. Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis. J Dermatolog Treat. 2025;36(1):2452987. doi:10.1080/09546634.2025.2452987 [PubMed 39870387]
  43. Guex-Crosier Y, Di-Lucca J, Häusermann P, et al. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients. Swiss Med Wkly. 2021;151:w30020. doi:10.4414/SMW.2021.w30020 [PubMed 34495603]
  44. Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139-147. doi:10.1016/j.jaad.2020.08.051 [PubMed 32822798]
  45. Han MK. Management of refractory chronic obstructive pulmonary disease. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed April 23, 2025.
  46. Hong N, Park SY, Kook HD, et al. Atopic dermatitis treated safely with dupilumab during pregnancy and lactation: a case series of four patients. Australas J Dermatol. 2024;65(4):e100-e103. doi:10.1111/ajd.14255 [PubMed 38509808]
  47. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
  48. Jackson K, Bahna SL. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Expert Rev Clin Immunol. 2020;16(3):311-319. doi:10.1080/1744666X.2020.1724089 [PubMed 31994421]
  49. Jasti VV, McCarthy ST, Govani SM. Dupilumab-induced pancreatitis. ACG Case Rep J. 2023;10(7):e01106. doi:10.14309/crj.0000000000001106 [PubMed 37492485]
  50. Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339-1347. doi:10.1016/j.jaad.2021.01.012 [PubMed 33428978]
  51. Jorge E, Clark J. Dupilumab for off-label treatment of moderate to severe childhood atopic dermatitis. Cutis. 2018;102(3):201-204. [PubMed 30372706]
  52. Kage P, Simon JC, Treudler R. A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. J Eur Acad Dermatol Venereol. 2020;34(6):e256-e257. doi:10.1111/jdv.16235 [PubMed 31990389]
  53. Kage P, Simon JC, Treudler R. Case of atopic eczema treated with dupilumab throughout conception, pregnancy, and lactation. J Dermatol. 2021;48(10):E484-E485. doi:10.1111/1346-8138.16033 [PubMed 34342905]
  54. Khamisy-Farah R, Damiani G, Kong JD, Wu JH, Bragazzi NL. Safety profile of dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™). Eur Rev Med Pharmacol Sci. 2021;25(17):5448-5451. doi:10.26355/eurrev_202109_26652 [PubMed 34533820]
  55. Kim H, Oh S, Noh H, et al. Appropriate injection intervals of dupilumab in patients with adult atopic dermatitis: a step toward developing guidelines for daily practice. Ann Dermatol. 2025;37(1):39-45. doi:10.5021/ad.24.084 [PubMed 39894672]
  56. Kuo ME, Briones NF, Helfrich YR. Infectious pseudochromhidrosis in the setting of dupilumab use. JAAD Case Rep. 2022;25:27-29. doi:10.1016/j.jdcr.2022.05.007 [PubMed 35712045]
  57. Lavin L, Chefitz G, Patel D, Baek WK, Khattri S. Severe cutaneous reaction with initiation of dupilumab for atopic dermatitis and prurigo nodularis: an unusual adverse effect. JAAD Case Rep. 2024;49:40-43. doi:10.1016/j.jdcr.2024.04.023 [PubMed 38883166]
  58. Lieberman JA, Chu DK, Ahmed T, et al. A systematic review and expert Delphi consensus recommendation on the use of vaccines in patients receiving dupilumab: a position paper of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2024;133(3):286-294. doi:10.1016/j.anai.2024.05.014 [PubMed 38848870]
  59. Lommatzsch M, Stoll P, Winkler J, et al. Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab-induced hypereosinophilia. Allergy. 2021;76(9):2920-2923. doi:10.1111/all.14964 [PubMed 34047387]
  60. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
  61. Luo N, Wang Q, Lei M, Li Z, Li T, Hao P. Burning and scaling probably associated with dupilumab therapy: a case report. Clin Cosmet Investig Dermatol. 2022;15:1659-1662. doi:10.2147/CCID.S373997 [PubMed 36000004]
  62. Mastorino L, Gelato F, Richiardi I, et al. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: a safe and effective practice? J Eur Acad Dermatol Venereol. 2023;37(5):e691-e692. doi:10.1111/jdv.18908 [PubMed 36688263]
  63. Matsuda T, Yamada H, Hida N, et al. An asthmatic case of psoriasiform eruption caused by administration of dupilumab. Allergol Int. 2020;69(3):478-479. doi:10.1016/j.alit.2020.02.004 [PubMed 32178985]
  64. Menzella F, Montanari G, Patricelli G, et al. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag. 2019;15:869-875. doi:10.2147/TCRM.S207402 [PubMed 31371974]
  65. Metko D, Alkofide M, Abu-Hilal M. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities. JAAD Int. 2024;15:5-11. doi:10.1016/j.jdin.2024.01.002 [PubMed 38371662]
  66. Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019 [PubMed 31699837]
  67. Mustin DE, Cole EF, Blalock TW, Kalangara ME, Stoff BK, Feldman RJ. Dupilumab-induced erythema nodosum. JAAD Case Rep. 2021;19:41-43. doi:10.1016/j.jdcr.2021.11.007 [PubMed 34917722]
  68. Muzumdar S, Zubkov M, Waldman R, DeWane ME, Wu R, Grant-Kels JM. Characterizing dupilumab facial redness in children and adolescents: a single-institution retrospective chart review. J Am Acad Dermatol. 2020;83(5):1520-1521. doi:10.1016/j.jaad.2020.06.1003 [PubMed 32622143]
  69. Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2020;104(6):776-779. doi:10.1136/bjophthalmol-2019-315010 [PubMed 31554632]
  70. Nakazaki K, Yoshida M, Masamoto Y, et al. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. Int J Hematol. 2022;116(3):446-452. doi:10.1007/s12185-022-03330-y [PubMed 35355217]
  71. Nguyen MT, Tsukikawa M, Lomazow W, Lee M. Irreversible bilateral cicatricial keratoconjunctivitis after dupilumab therapy. Case Rep Ophthalmol. 2022;13(2):638-642. doi:10.1159/000525738 [PubMed 36160495]
  72. Nitro L, Bulfamante AM, Rosso C, et al. Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review. Acta Otorhinolaryngol Ital. 2022;42(3):199-204. doi:10.14639/0392-100X-N1911 [PubMed 35880360]
  73. Paller AS. Treatment of atopic dermatitis (eczema). Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed April 23, 2025.
  74. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi:10.1155/2012/985646 [PubMed 22235228]
  75. Patruno C, Potestio L, Fabbrocini G, Napolitano M. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis. Dermatol Ther. 2022;35(12):e15933. doi:10.1111/dth.15933 [PubMed 36227462]
  76. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328-344. doi:10.1002/bdrb.20201 [PubMed 19626656]
  77. Persaud P, Karmali R, Sankar P, Majid M. Dupilumab-associated eosinophilic granulomatosis with polyangiitis. Cureus. 2022;14(8):e27670. doi:10.7759/cureus.27670 [PubMed 36072184]
  78. Pfaller B, José Yepes-Nuñez J, Agache I, et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. Allergy. 2021;76(1):71-89. doi:10.1111/all.14282 [PubMed 32189356]
  79. Phelps-Polirer K, Alkhatib BL, Davis C. Generalized granuloma annulare associated with dupilumab therapy. Cureus. 2022;14(7):e27439. doi:10.7759/cureus.27439 [PubMed 36051735]
  80. Phylactou M, Jabbour S, Ahmad S, Vasquez-Perez A. Corneal perforation in patients under treatment with dupilumab for atopic dermatitis. Cornea. 2022;41(8):981-985. doi:10.1097/ICO.0000000000002854 [PubMed 34928552]
  81. Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2023;151(2):386-398. doi:10.1016/j.jaci.2022.10.026 [PubMed 36370881]
  82. Reddy AK, Hauswirth SG, Gregory DG, Liao SD, Palestine AG. Dupilumab-associated cicatrizing ocular disease. Am J Ophthalmol Case Rep. 2022;26:101528. doi:10.1016/j.ajoc.2022.101528 [PubMed 35479518]
  83. Refer to manufacturer's labeling.
  84. Russo F, Provvidenziale L, Bruzziches F, et al. Psoriasis-like eruption triggered by dupilumab therapy. Dermatitis. 2021;32(6):e147-e148. doi:10.1097/DER.0000000000000740 [PubMed 34310097]
  85. Schneeweiss MC, Kim SC, Wyss R, Schneeweiss S, Merola JF. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study. J Am Acad Dermatol. 2021;84(2):300-311. doi:10.1016/j.jaad.2020.09.084 [PubMed 33038471]
  86. Shakuntulla F, Chiarella SE. Safety of biologics for atopic diseases during pregnancy. J Allergy Clin Immunol Pract. 2022;10(12):3149-3155. doi:10.1016/j.jaip.2022.08.013 [PubMed 35987486]
  87. Sharma S. Treatment of severe asthma in adolescents and adults. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed April 23, 2025.
  88. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
  89. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348. [PubMed 27690741]
  90. Spekhorst LS, Boesjes CM, Loman L, et al. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry. Br J Dermatol. 2023;189(3):327-335. doi:10.1093/bjd/ljad159 [PubMed 37177895]
  91. Tamura T, Okano H, Koyanagi T, Umeno T, Nishii K, Kuyama S. Dupilumab-induced diffuse alveolar hemorrhage. Intern Med. 2025;64(1):109-112. doi:10.2169/internalmedicine.3695-24 [PubMed 38749726]
  92. Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208-1211. doi:10.1001/jamadermatol.2018.269 [PubMed 30167653]
  93. Treister AD, Lio PA. Long-term off-label dupilumab in pediatric atopic dermatitis: a case series. Pediatr Dermatol. 2019;36(1):85-88. [PubMed 30338546]
  94. Treudler R, Delaroque N, Puder M, Simon JC, Szardenings M. Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema. J Eur Acad Dermatol Venereol. 2021;35(1):e30-e32. doi:10.1111/jdv.16782 [PubMed 32594596]
  95. Tsitos S, Niederauer LC, Albert I Gracenea P, Mueller J, Straube A, Von Baumgarten L. Case report: drug-induced (neuro) sarcoidosis-like lesion under IL4 receptor blockade with dupilumab. Front Neurol. 2022;13:881144. doi:10.3389/fneur.2022.881144 [PubMed 35795795]
  96. van der Lans RJL, Fokkens WJ, Adriaensen GFJPM, Hoven DR, Drubbel JJ, Reitsma S. Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy. 2022;77(2):670-674. doi:10.1111/all.15134 [PubMed 34626497]
  97. Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-1659. doi:10.1111/jdv.15709 [PubMed 31231864]
  98. Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230-232. doi:10.1016/j.jaad.2019.06.026 [PubMed 31228530]
  99. Wang Y, Jorizzo JL. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration. J Am Acad Dermatol. 2021;84(4):1010-1014. doi:10.1016/j.jaad.2020.11.042 [PubMed 33725800]
  100. Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma Clin Immunol. 2018;14(suppl 2):60. doi:10.1186/s13223-018-0289-y [PubMed 30275849]
  101. Watsky K. Prurigo nodularis. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed April 23, 2025.
  102. Wilson MM, Roberts PK, Daniell M. Dupilumab-associated ulcerative keratitis. Int J Ophthalmol. 2022;15(6):1020-1022. doi:10.18240/ijo.2022.06.23 [PubMed 35814891]
  103. Wu L, Ali K, Qiu Y, Li M, Da J. Dupilumab-induced acute generalized exanthematous pustulosis in a 17-year-old female Chinese patient with atopic dermatitis. Acta Derm Venereol. 2022;102:adv00743. doi:10.2340/actadv.v102.1079 [PubMed 35670324]
Topic 112484 Version 228.0